{
    "ticker": "ZBIO",
    "name": "Zymeworks Inc.",
    "description": "Zymeworks Inc. is a clinical-stage biopharmaceutical company focused on creating next-generation therapeutics for the treatment of cancer and other serious diseases. Founded in 2003 and headquartered in Vancouver, Canada, Zymeworks leverages its proprietary Zymeworks Platform\u2122 to develop multifunctional therapeutics that can provide improved efficacy and reduced side effects compared to traditional therapies. The company is known for its innovative approach to drug development, utilizing advanced protein engineering and a modular design to create biotherapeutics that can be tailored to the specific needs of patients and diseases. Zymeworks is actively advancing a robust pipeline of product candidates, including ZW25, a bispecific antibody designed to target a specific type of cancer, and ZYNLONTA, an investigational therapy for hematologic malignancies. The company is committed to improving patient outcomes by delivering safer and more effective treatment options, and it collaborates with various partners in the biopharmaceutical industry to enhance its research and development capabilities. With a strong emphasis on innovation and patient-centric solutions, Zymeworks aims to be a leader in the biopharmaceutical space, addressing unmet medical needs and contributing to the advancement of cancer treatment.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, British Columbia, Canada",
    "founded": "2003",
    "website": "https://www.zymeworks.com",
    "ceo": "Ali Tehrani",
    "social_media": {
        "twitter": "https://twitter.com/Zymeworks",
        "linkedin": "https://www.linkedin.com/company/zymeworks/"
    },
    "investor_relations": "https://investors.zymeworks.com",
    "key_executives": [
        {
            "name": "Ali Tehrani",
            "position": "CEO"
        },
        {
            "name": "Gavin O. MacBeath",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antibody Therapeutics",
            "products": [
                "ZW25",
                "ZYNLONTA"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zymeworks Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Discover Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation therapeutics for cancer treatment. Explore our innovative pipeline and commitment to patient-centric solutions.",
        "keywords": [
            "Zymeworks",
            "Biopharmaceuticals",
            "Cancer Treatment",
            "Antibody Therapeutics",
            "ZW25",
            "ZYNLONTA"
        ]
    },
    "faq": [
        {
            "question": "What is Zymeworks known for?",
            "answer": "Zymeworks is known for developing next-generation biopharmaceuticals for cancer treatment."
        },
        {
            "question": "Who is the CEO of Zymeworks?",
            "answer": "Ali Tehrani is the CEO of Zymeworks Inc."
        },
        {
            "question": "Where is Zymeworks headquartered?",
            "answer": "Zymeworks is headquartered in Vancouver, British Columbia, Canada."
        },
        {
            "question": "What are Zymeworks' main products?",
            "answer": "Zymeworks' main products include ZW25 and ZYNLONTA."
        },
        {
            "question": "When was Zymeworks founded?",
            "answer": "Zymeworks was founded in 2003."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "GILD",
        "BMY",
        "JNJ",
        "PFE"
    ]
}